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Abstract
Mercury is toxic to the kidney, and dental amalgam is a source of mercury exposure. Few studies
have evaluated the effects of dental amalgam on kidney function in a longitudinal context in
children. Here, we evaluated urinary concentrations of glutathione S-transferases (GSTs) α and π
as biomarkers of renal proximal and distal tubular integrity, respectively, and albumin as a
biomarker of glomerular integrity in children and adolescents 8-18 years of age over a 7 year
course of dental amalgam treatment. Five hundred seven children, 8-12 years of age at baseline,
participated in a clinical trial to evaluate the neurobehavioral and renal effects of dental amalgam
in children. Subjects were randomized to either dental amalgam or resin composite treatments.
Urinary GSTs α and π, albumin and creatinine concentrations were measured at baseline and
annually on all subjects. Results were evaluated using linear regression analysis. GST-α
concentrations were similar between treatment groups and in each sex and race (white vs non-
white) group in each follow-up year. GST-π levels tended upward over the course of follow-up by
4- to 6-fold. This increase was seen in all groups irrespective of treatment, race or gender. Females
had GST-π levels approximately twice those of males at all ages. Albumin concentrations were
constant throughout the follow-up period and did not differ by treatment, although females had
39% higher albumin levels than males. Additionally, we found no significant effects of amalgam
treatment on the proportion of children with microalbuminuria (>30 mg/g creatinine). These
findings are relevant within the context of children’s health risk assessment as relates to the safety
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of mercury exposure from dental amalgam on kidney function. These data also provide normative
values for sensitive indices of renal functional integrity that may serve in the evaluation of
children and adolescents with renal disorders.
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INTRODUCTION
The renal tubular system is comprised of several segments with highly specialized functions
(Schmidt and Guder, 1976), each differentially sensitive to injury by drugs and
environmental chemicals. The release of cytoplasmic proteins and other constituents into the
urine following injury to tubular cells has long been clinically exploited to assess the site
and severity of renal tubular damage associated with disease and toxicant exposures
(Bernard and Lauwerys, 1991; Woods, 1996; Zhou et al., 2008). Among the proteins of
longstanding utility in the assessment of renal injury are the glutathione S-transferases
(GSTs) (Feinfeld et al., 1984; Sundberg et al., 1994), most of which are found in soluble
form in the cytosolic fraction of tubular epithelial cells. In humans, two GSTs of particular
interest as biomarkers of tubular damage are GST-alpha (GST-α), which is localized to the
proximal tubule (Bäckman et al., 1988; Campbell et al., 1991), and GST-pi (GST-π), found
in epithelial cells of the distal tubule and the collecting ducts (Sundberg et al., 1994).
Of additional interest as a biomarker of renal function and tubular integrity is albumin, a low
molecular weight plasma protein that is normally 99% reabsorbed by proximal tubular cells
following filtration by the glomerulus. The concentration of albumin in the urine is
commonly employed as a measure of both glomerular filtration and tubular reabsorptive
capacity (Remuzzi and Bertani, 1998) and, more currently, as a biomarker of incipient
tubulointerstitial damage associated with disease or nephrotoxicant exposure (Lambers
Heerspink et al., 2006; Ohse et al., 2006).
Elemental mercury (Hg0) is among the toxicants of particular concern in regard to tubular
injury (Zalups, 2000). A prominent source of Hg0 exposure in humans is dental amalgam
fillings, which are approximately 50% metallic mercury by weight. Hg0 vapor released from
amalgam fillings in tooth surfaces is readily absorbed into the systemic circulation by
inhalation (Berglund et al., 1988; Mackert and Berglund, 1997; Svare et al., 1981; Vimy and
Lorscheider, 1985). Once absorbed, Hg0 undergoes biotransformation predominantly in
erythrocytes to mercuric ion (Hg2+), the ultimate mediator of mercury toxicity (Halbach and
Clarkson, 1978; Magos et al., 1978). In humans and other mammals, the kidney represents a
primary target organ in which Hg2+ accumulates after Hg0 exposure, with highest
concentrations found in S-3 segment cells (pars recta) of the proximal tubule. The potential
adverse effects of low-level Hg0 exposure from dental amalgam, particularly in children,
remain a topic of continued debate (Brownawell et al., 2005; Clarkson and Magos, 2006).
Findings from two concurrently conducted clinical trials that were designed to evaluate the
potential health consequences of prolonged Hg0 exposure from dental amalgam fillings in
children have been recently reported (Bellinger et al., 2006; DeRouen et al., 2006). As part
of one of those trials (DeRouen et al., 2006), we performed annual measurements of urinary
GSTs and albumin concentrations in children between 9 and 18 years of age as an
assessment of potential kidney injury associated with prolonged Hg0 exposure. Here we
describe measures of urinary GSTs and albumin concentrations in children with and without
amalgam fillings over the course of the trial. We also report age-related changes and race-
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and sex-related differences in these parameters in children and adolescents with and without
amalgam treatment.
MATERIALS AND METHODS
Description of the study population
The children’s cohort was derived from the recently completed Casa Pia clinical trial of the
health effects of dental amalgam fillings in children (DeRouen et al. 2006). Subjects (n=507)
were boys and girls (54:46%), 70% white, aged 8-12 at inception, who were residents of the
Casa Pia school system in Lisbon, Portugal. Subjects were initially randomized to mercury
amalgam (treatment) or composite resin (control) dental treatment groups. The study
protocol was approved by the institutional review boards at the University of Washington
and the University of Lisbon. All parents or guardians gave written consent, and all children
provided signed assent. Principal design and analytical issues involved in this trial
(DeRouen et al., 2002) as well as principal outcome measures (DeRouen et al., 2006) have
been reported.
Procedures for urine collection and measures of urinary GSTs, albumin and creatinine
Methods of urine collection for this study have been described (Woods et al., 2007).
Concentrations of GSTs α and π in urine samples were measured by enzyme immunoassay
employing kits purchased from Biotrin USA (Cedarknolls, NJ, USA). The assay procedure
is based on the sequential addition of sample, enzyme-conjugate and substrate to microtiter
wells coated with anti-α or anti-π GST IgG. A Molecular Devices UV-Max microplate
reader capable of 96 simultaneous UV absorbance determinations was employed for GST
quantitation. Urinary albumin was quantitated using a radial immunodiffusion assay (The
Binding Site, San Diego, CA, USA). Creatinine concentrations were measured using a
standard colorimetric procedure (Sigma #555-A; Sigma-Aldrich, St. Louis, MO, USA). The
number of subjects differed between Tables 1, 3 and 5 because of variation in the number
successful assays for GSTα, GSTπ and albumin, respectively.
Statistical procedures
Analyses were performed on log-transformed concentrations, as is common practice for
analyzing concentration data, to account for positive skewness and heteroskedasticity
(variances increased with increasing mean value). Descriptive statistics were computed for
creatinine-adjusted values of GST-α, GST-π, and albumin on the natural logarithm scale by
treatment group and year of age. Eight year olds were excluded from age group-specific
analyses owing to too few subjects in this age group to permit analysis of associations with
statistical significance. Treatment groups were compared across years of age by fitting linear
regression models using generalized estimating equations (GEE) (Liang and Zeger, 1986) to
account for correlation between measures on the same subject at different ages. Separate
regression models were run for each of the three log-transformed concentrations (GST-α,
GST-π, and albumin) as outcome variables. The main predictor variable of interest was
treatment group (Amalgam versus Composite). The covariates in the models included the
log-transformed creatinine concentration in the sample, year of age (9-18) as a categorical
variable, the participant’s age at baseline in years, participant’s gender (female versus male),
and participant’s race (white versus non-white). Separate analyses were conducted with the
baseline values of the outcome variable and log-transformed creatinine as additional
covariates to further reduce the error variance and to adjust for group differences at baseline
that may have occurred despite the random treatment assignment. Notably, urinary mercury
was not included as a predictor variable in the analysis because doing so would deviate from
the randomized clinical trail design that allowed us to make inference regarding the cause-
effect relationship of amalgam mercury exposure and urinary GST or albumin levels. In this
Woods et al. Page 3
Environ Res. Author manuscript; available in PMC 2011 December 13.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
respect, our analyses rely on the strength of the randomized design to test for an effect of
amalgam exposure on GST and albumin. By comparing groups of children randomly
assigned to the different exposures, we avoid confounding of the relationships by other
observed or unobserved factors. Associations between observed urinary mercury levels and
GST or albumin would provide weaker evidence because they are susceptible to
confounding.
RESULTS
The demographic characteristics of subjects were similar in the two treatment groups, as
previously reported (DeRouen et al., 2006). Baseline mean creatinine-adjusted urinary
mercury levels were 1.8 μgrams/gram creatinine in the amalgam group and 1.9 μgrams/gram
creatinine in the composite group. Creatinine-adjusted GST-α levels were similar in the two
treatment groups and in each gender group in each year of age, as shown in Table 1.
Regression analysis, presented in Table 2 (Model I), showed that GST-α levels were
approximately 5% higher in the Amalgam group compared with the Composite group, but
this difference was not statistically significant. Females had 11% higher GST-α levels than
males (p = 0.05), and non-whites had about 13% higher levels than whites (p = 0.04). The
gender and race effects became non-significant, however, after adjustment for baseline
values (Model II), indicating that differences in GST-α during follow-up based on gender
and race can be attributed to differences already present at baseline.
As shown in Table 3, creatinine-adjusted GST-π levels tended to increase over the course of
the study by 4- to 6- fold from 9 to 18 years of age. This increase was observed in all groups
irrespective of treatment or gender. At each age, differences between groups in GST-π levels
tended to be small and similar to those for GST-α. Regression analysis (Table 4) showed
that GST-π levels were approximately 11% higher in the Amalgam group overall (p = 0.04)
(Model II). Notably, females had GST-π levels approximately twice as high as those of
males (p < 0.0001). The gender difference was essentially unchanged by adjustment for
baseline values (Model II) because of the weak association between baseline and follow-up
values of GST-π. Whites had slightly higher levels than non-whites, and this difference,
although small, became significant (p = 0.025) following adjustment for baseline values.
As shown in Table 5, differences between groups in creatinine-adjusted albumin levels were
small for all years of age. Albumin levels were slightly lower in the Amalgam group than in
the Composite group, but the group effect was not statistically significant in the regression
analysis (Table 6). Females had approximately 39% higher albumin levels than males (p <
0.0001). The gender difference was unchanged by adjustment for baseline values (Model II),
which is surprising because there was a significant association between baseline and follow-
up values of albumin (p < 0.001), and there was a gender difference in baseline values of
albumin of approximately the same magnitude as the difference during follow-up. There was
a significant difference between whites and non-whites (with higher levels for whites than
non-whites) (Table 6, Model I). However, this difference was reduced and became non-
significant after adjustment for baseline values (Model II).
Figure 1 provides a graphical representation of changes in creatinine-adjusted GST α, GST π
and albumin by year-of-age and treatment group (left) and by year-of-age and gender (right).
This presentation emphasizes the findings of no significant differences in any of these
parameters when comparing treatment groups, and shows the progressive increase in GST π
that occurs between the ages of 9 and 18 in all groups. This figure also shows the
significantly greater creatinine-adjusted GST π and albumin, but not GST α, excreted by
females compared with males throughout the course of follow-up from ages 9 through 18.
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The findings for all parameters described herein were comparable when evaluated as follow-
up year instead of year of age.
DISCUSSION
Numerous studies have characterized the association of urinary proteins and other cellular
constituents with changes in renal tubular integrity associated with disease or nephrotoxicant
exposures in both adults and children (de Burbure et al., 2002; Tomlison, 1992;
Trachtenberg and Barregård, 2007). This is the first study to our knowledge to describe
urinary GST concentrations in children during the longitudinal course of amalgam treatment
from childhood through late adolescence. The findings suggest no deleterious effects of
mercury exposure from dental amalgam on either proximal or distal tubule cellular integrity,
as indicated by the lack of significant differences in either GST α or π, respectively, between
amalgam and composite groups over a prolonged course of treatment. While other measures
of tubular integrity were not evaluated in this study, these findings are consistent with those
of Barregard et al., (2008) who reported no changes in alpha-1-microglobulin, γ-glutamyl
transpeptidase or N-acetyl-β-D-glucosaminidase in children participating in the New
England Children’s Amalgam Trial (NECAT), conducted concurrently with the present
study. Comparable findings by de Burbure et al., (2003) suggested that no renal lesions
appear to occur in children with mean urinary Hg levels up to 13.4 μg/g creatinine and a
maximum of 25 μg/g creatinine. As previously reported (Woods et al., 2007), the mean peak
urinary Hg concentration observed among children in the present study population was 3.5
μg/g creatinine.
Of interest is the observation that creatinine-adjusted urinary GST-α concentrations
remained relatively constant throughout the course of later childhood and adolescence,
whereas urinary GST-π increased progressively with age and show substantial gender
differences. Although the physiological processes underlying the renal handling of these
proteins remain largely unknown, the transcriptional regulation of specific GSTs in humans
is understood to be subject to independent arrays of developmental-, sex- and tissue-specific
factors (Eaton and Bammler, 1999), possibly accounting for the age- and/or sex-related
differences in the expression of GSTs α and π observed in this study. While supporting the
absence of adverse effects of amalgam mercury exposure on kidney function, these findings
are of additional interest in establishing normative values for these measures of proximal
and distal tubular integrity, respectively, in children and adolescents.
Although immunologic reactions to mercury are exceedingly rare, mercury-induced
autoimmune responses that can lead to glomerulonephritis have been reported (Druet et al.,
1982). To this end, we measured urinary albumin concentrations in subjects in the Casa Pia
study as an assessment of potential glomerular injury associated with amalgam treatment. As
reported in Tables 5 and 6, we found no significant effects of prolonged amalgam mercury
exposure on glomerular integrity as assessed by urinary albumin measurements performed
during the course of treatment and follow-up. Similar findings have been reported by other
investigators who evaluated urinary albumin excretion in relation to amalgam mercury
exposure among healthy human subjects (Herrström et al., 1995; Langworth et al., 1997;
Sandborgh-Englund et al., 1996). In contrast, Barregard et al., (2008) reported a
significantly higher proportion of children with microalbuminuria (i.e., > 30 mg/g
creatinine) among those receiving dental amalgam treatment compared with those receiving
composite resin fillings during the 3rd and 5th years of follow-up in the NECAT study.
Using the same metrics (creatinine-adjusted albumin >30 mg/gm) reported therein, in
addition to comparison of median urinary albumin values previously reported (DeRouen et
al., 2006), our analyses revealed no significant effects of amalgam treatment on the
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proportion of children with microalbuminuria in the present study. These finding are
described in Table 7.
In conclusion, we observed no significant effects of dental amalgam mercury on measures of
renal tubular or glomerular functional integrity during a prolonged course of dental amalgam
treatment in children and adolescents from 9 to 18 years of age. These findings are relevant
within the context of children’s health risk assessment as relates to the safety of mercury
exposure from dental amalgam on kidney function. Additionally, these data provide
normative values for sensitive indices of renal functional integrity that may serve in the
evaluation of children and adolescents with renal disorders.
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Figure 1.
Urinary concentrations of log-transformed creatinine-adjusted GST-α, GST-π, and Albumin
means by age and treatment group (left) or age and gender (right).
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Table 2
Regression analysis of log-transformed GST-α concentrations for ages 9-18.
Model Term
Model I Model II
Estimate* (95%
CI) p-value
Estimate* (95%
CI) p-value
Age:
 9 7.08 (3.87, 12.97) <0.001 5.36 (2.68, 10.73) <0.001
 10 7.08 (3.92, 12.80) <0.001 5.53 (2.84, 10.79) <0.001
 11 6.28 (3.44, 11.46) <0.001 4.88 (2.47, 9.65) <0.001
 12 5.91 (3.21, 10.87) <0.001 4.75 (2.36, 9.54) <0.001
 13 5.72 (3.10, 10.56) <0.001 4.38 (2.17, 8.83) <0.001
 14 5.30 (2.87, 9.77) <0.001 3.94 (1.96, 7.92) 0.001
 15 5.52 (2.99, 10.19) <0.001 4.60 (2.30, 9.19) <0.001
 16 5.28 (2.80, 9.94) <0.001 4.25 (2.06, 8.77) <0.001
 17 5.27 (2.80, 9.93) <0.001 4.15 (2.01, 8.59) 0.001
 18 5.75 (2.93, 11.28) <0.001 4.43 (2.03, 9.63) 0.002
Amalgam Group (vs.
Composite) 1.05 (0.95, 1.17) 0.308 1.05 (0.94, 1.17) 0.405
Female Gender (vs. Male) 1.11 (1.00, 1.23) 0.047 1.03 (0.91, 1.15) 0.653
White Race (vs. Non-white) 0.89 (0.79, 0.99) 0.035 0.96 (0.85, 1.08) 0.502
Age at baseline (years) 1.02 (0.96, 1.08) 0.452 1.02 (0.95, 1.08) 0.642
Log Creatinine (concurrent) 1.17 (1.09, 1.25) <0.001 1.17 (1.08, 1.27) <0.001
Log Creatinine (baseline) NA NA 0.93 (0.84, 1.04) 0.211
Log GST-α (baseline) NA NA 1.22 (1.15, 1.29) <0.001
*
exponentiated
Models I and II represent regressions performed before and after adjustment for baseline values, respectively.
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Table 4
Regression analysis of log-transformed GST-π concentrations for ages 9-18.
Model Term
Model I Model II
Estimate* (95%
CI) p-value
Estimate* (95%
CI) p-value
Age:
 9 10.06 ( 4.85, 20.84) <0.001 7.99 ( 3.21,19.88) <0.001
 10 10.95 ( 5.34, 22.45) <0.001 8.17 ( 3.40,19.64) <0.001
 11 14.59 ( 7.04, 30.22) <0.001 11.01 ( 4.55,26.64) <0.001
 12 19.54 ( 9.10, 41.94) <0.001 15.05 ( 5.96,37.96) <0.001
 13 24.13 (11.18,52.10) <0.001 20.07 ( 7.93,50.78) <0.001
 14 29.59 (13.73,63.76) <0.001 22.68 ( 8.86,58.03) <0.001
 15 45.30 (21.96,93.48) <0.001 35.44 (14.77,85.06) <0.001
 16
65.10 (30.87,
137.33) <0.001
50.47 (20.57,
123.78) <0.001
 17
71.74 (32.67,
157.50) <0.001
57.49 (22.42,
147.42) <0.001
 18
93.20 (41.08,
211.45) <0.001
66.84 (25.05,
178.34) <0.001
Amalgam Group (vs.
Composite) 1.08 ( 0.96, 1.20) 0.203 1.11 ( 0.98, 1.26) 0.091
Female Gender (vs. Male) 2.04 ( 1.83, 2.29) <0.001 2.01 ( 1.78, 2.28) <0.001
White Race (vs. Non-white) 1.11 ( 0.98, 1.26) 0.105 1.17 ( 1.02, 1.34) 0.025
Age at baseline (years) 0.81 ( 0.76, 0.87) <0.001 0.83 ( 0.76, 0.90) <0.001
Log Creatinine (concurrent) 1.75 ( 1.59, 1.93) <0.001 1.81 ( 1.63, 2.02) <0.001
Log Creatinine (baseline) NA NA 0.98 ( 0.87, 1.09) 0.689
Log GST-π (baseline) NA NA 1.03 ( 0.97, 1.10) 0.353
*
exponentiated
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Table 6
Regression analysis of log-transformed urinary albumin concentrations for ages 9-18.
Model Term
Model I Model II
Estimate* (95%
CI) p-value
Estimate* (95%
CI) p-value
Age:
 9 9.55 (4.74, 19.27) <0.001 4.33 (1.70, 10.99) 0.002
 10 7.88 (3.75, 16.54) <0.001 4.08 (1.52, 10.94) 0.005
 11 7.90 (3.81, 16.41) <0.001 4.21 (1.63, 10.89) 0.003
 12 9.69 (4.67, 20.15) <0.001 5.10 (1.95, 13.29) 0.001
 13 11.88 (5.67, 24.88) <0.001 6.32 (2.40, 16.66) <0.001
 14 10.34 (4.94, 21.64) <0.001 5.45 (2.08, 14.27) 0.001
 15 10.52 (4.99, 22.18) <0.001 5.25 (2.00, 13.74) 0.001
 16 9.61 (4.51, 20.48) <0.001 5.15 (1.89, 14.01) 0.001
 17 10.14 (4.75, 21.65) <0.001 5.03 (1.85, 13.66) 0.002
 18 9.62 (4.26, 21.72) <0.001 4.51 (1.49, 13.66) 0.008
Amalgam Group (vs.
Composite) 0.92 (0.82, 1.04) 0.179 0.91 (0783, 1.07) 0.274
Female Gender (vs. Male) 1.38 (1.22, 1.56) <0.001 1.39 (1.18, 1.63) <0.001
White Race (vs. Non-white) 1.16 (1.02, 1.32) 0.023 1.10 (0.94, 1.28) 0.229
Age at baseline (years) 0.97 (0.90, 1.03) 0.311 0.98 (0.90, 1.06) 0.556
Log Creatinine (concurrent) 2.13 (1.90, 2.37) <0.001 2.25 (1.97, 2.56) <0.001
Log Creatinine (baseline) NA NA 0.77 (0.62, 0.96) 0.020
Log albumin (baseline) NA NA 1.29 (1.15, 1.45) <0.001
*
exponentiated
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Table 7
Creatinine-adjusted urinary albumin by treatment group for creatinine > 30 mg/gm creatinine.
Albumin/creatinine > 30 during follow up
Age Amalgamevents / visits
Composite
events / visits
Odds Ratio
(amal/comp) p-value
9 3 / 32 5 / 37 0.7 0.72
10 4 / 95 13 / 107 0.3 0.52
11 12 / 182 15 / 178 0.8 0.69
12 21 / 231 26 / 230 0.8 0.67
13 33 / 235 37 / 229 0.8 0.70
14 22 / 206 26 / 224 0.9 0.78
15 18 / 197 33 / 211 0.5 0.52
16 17 / 158 17 / 132 0.8 0.72
17 14 / 103 8 / 83 1.5 0.66
18 3 / 30 3 / 29 1.0 0.83
Wald tests were used to test for a difference in the log odds of albumin/creatinine > 30 (odds ratio different from 1) at each age during follow-up.
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